

Agile Therapeutics Fourth Quarter & Full Year 2022 Earnings Call

March 22, 2023

Forward-Looking Statements


Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding our ongoing and planned manufacturing and commercialization of Twirla[®], the potential market acceptance and uptake of Twirla[®], including the increasing demand for Twirla in 2023, our partnership with Afaxys and its ability to promote growth, our product supply agreement with Nurx and its ability to educate patients about Twirla, our connected TV (CTV) campaign and its ability to promote growth, our prospects for future financing arrangements, our net revenue and expected operating expenses for 2023, and our financial condition, growth and strategies. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to our ability to maintain regulatory approval of Twirla and the labeling under any approval we obtain, the ability of Corium to produce commercial supply in quantities and quality sufficient to satisfy market demand for Twirla, our ability to successfully enhance the commercialization of and increase the uptake for Twirla, the size and growth of the markets for Twirla and our ability to serve those markets, regulatory and legislative developments in the United States and foreign countries, our ability to obtain and maintain intellectual property protection for Twirla and our product candidates, the effects of the lingering COVID-19 pandemic on our commercialization efforts, clinical trials, supply chain, operations and the operations of third parties we rely on for services such as manufacturing, marketing support and sales support, as well as on our potential customer base, our ability to maintain compliance with the listing requirements of the Nasdaq Capital Market, and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this presentation. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Twirla Performance Update


Twirla Momentum: Business Plan is Performing

	Q4 2022	Q3 2022	% Change
Net Revenue (vs. Q3 2022)	\$4.0M	\$3.0M	+33%
	Full Year 2022	Full Year 2021	% Change
Net Revenue (vs. Full Year 2021)	\$10.9M	\$4.1M	+165%

Twirla Demand Momentum: Business Plan is Performing



Consecutive Quarters of Accelerated Factory Sales Growth (Cycles) and Managed Non-GAAP OPEX



Reconciliations of GAAP to non-GAAP financial measures are available in our fourth quarter 2022 earnings press release and elsewhere in this presentation.

Twirla Momentum: Business Plan is Performing

Q4 2022 vs. Q3 2022

	Q4 2022	Q3 2022	% Change
Net Revenue	\$4.0M	\$3.0M	+33%
Non-GAAP OPEX	\$9.2M	\$9.2M	0%

Full Year 2022 vs. Full Year 2021

	Full Year 2022	Full Year 2021	% Change
Net Revenue	\$10.9M	\$4.1M	+165%
Non-GAAP OPEX	\$45.5M	\$64.4M	-29%

Q4 2022 vs. Q4 2021

	Q4 2021	% Change
Net Revenue	\$1.5M	+167%
Non-GAAP OPEX	\$18.2M	-49%

**2023 Net Revenue
Expected to be
\$25-\$30M**

Reconciliations of GAAP to non-GAAP financial measures are available in our fourth quarter 2022 earnings press release and elsewhere in this presentation.

Twirla Business Plan Update

Additional Twirla Upside Potential for 2023

Business Plan
for Growth
in 2023

Non-Retail Growth Driver



Retail Growth Drivers



**We Believe Strategic Partnerships Will
Continue to Help us Expand Our Business**

Potential Upside
for Growth



**In 2023, Agile is Actively Pursuing Business
Development Opportunities**

**Focused on Adding Commercial Women's Health
Products that can Potentially Reduce the Timeline
Required to Generate Positive Cash Flow**

**Grow Twirla
&
Generate
Positive Company
Cash Flow**

Finance Update

Q&A

Closing Remarks

Reconciliations of GAAP to Non-GAAP Financial Measures

	Three Months Ended					Twelve Months Ended	
	12/31/2022	9/30/2022	6/30/2022	3/31/2022	12/31/2021	12/31/2022	12/31/2021
GAAP Operating expenses	\$ 9,219	20,285	11,293	15,807	18,170	\$ 56,604	\$ 64,388
Non-GAAP adjustment: Loss on disposition of assets	\$ -	11,122	-	-	-	\$ 11,122	-
Non-GAAP operating expenses	\$ 9,219	9,163	11,293	15,807	18,170	\$ 45,482	\$ 64,388

	Three Months Ended					Twelve Months Ended	
	3/31/2022 (Restated)	6/30/2022 (Restated)	9/30/2022 (Restated)	12/31/2022	12/31/2021 (Restated)	12/31/2022	12/31/2021 (Restated)
GAAP Net Loss	\$ (10,385)	(5,168)	(5,930)	(3,929)	(19,531)	\$ (25,412)	\$ (71,067)
Unrealized gain on warrant liability	1,384	7,051	13,736	3,349	3,827	25,520	3,827
Loss on disposition of assets	-	-	(11,122)	-	-	(11,122)	-
Non-GAAP Net Loss	\$ (11,769)	(12,219)	(8,544)	(7,278)	(23,358)	\$ (39,810)	\$ (74,894)
Non-GAAP Net Loss Per Share	\$ (3.78)	(2.71)	(0.23)	(0.18)	(7.92)	\$ (1.84)	\$ (30.86)
Weighted avg shares	3,115,211	4,510,219	36,997,836	41,232,562	2,947,944	21,610,947	2,426,821